HEADER TRANSFERASE 10-AUG-00 1FKO TITLE CRYSTAL STRUCTURE OF NNRTI RESISTANT K103N MUTANT HIV-1 REVERSE TITLE 2 TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ) COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 RT, A-CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: P66; COMPND 5 EC: 2.7.7.49; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 OTHER_DETAILS: COMPLEXED WITH DMP-266(EFAVIRENZ); COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: HIV-1 RT, B-CHAIN; COMPND 11 CHAIN: B; COMPND 12 FRAGMENT: P51; COMPND 13 EC: 2.7.7.49; COMPND 14 ENGINEERED: YES; COMPND 15 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 STRAIN: HXB2 ISOLATE; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 9 ORGANISM_TAXID: 11676; SOURCE 10 STRAIN: HXB2 ISOLATE; SOURCE 11 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS HIV-1 REVERSE TRANSCRIPTASE, AIDS, NON-NUCLEOSIDE INHIBITOR, DMP-266, KEYWDS 2 EFAVIRENZ, DRUG RESISTANCE MUTATION, DRUG DESIGN, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR J.REN,J.MILTON,K.L.WEAVER,S.A.SHORT,D.I.STUART,D.K.STAMMERS REVDAT 9 30-OCT-24 1FKO 1 REMARK SEQADV LINK REVDAT 8 14-MAR-18 1FKO 1 SEQADV REVDAT 7 31-JAN-18 1FKO 1 JRNL REVDAT 6 18-JUL-12 1FKO 1 HETSYN VERSN REVDAT 5 24-FEB-09 1FKO 1 VERSN REVDAT 4 28-DEC-04 1FKO 1 HETATM REMARK REVDAT 3 06-JAN-04 1FKO 1 SOURCE JRNL REMARK MODRES REVDAT 2 28-FEB-01 1FKO 3 ATOM REMARK REVDAT 1 03-NOV-00 1FKO 0 JRNL AUTH J.REN,J.MILTON,K.L.WEAVER,S.A.SHORT,D.I.STUART,D.K.STAMMERS JRNL TITL STRUCTURAL BASIS FOR THE RESILIENCE OF EFAVIRENZ (DMP-266) JRNL TITL 2 TO DRUG RESISTANCE MUTATIONS IN HIV-1 REVERSE TRANSCRIPTASE. JRNL REF STRUCTURE FOLD.DES. V. 8 1089 2000 JRNL REFN ISSN 0969-2126 JRNL PMID 11080630 JRNL DOI 10.1016/S0969-2126(00)00513-X REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.REN,C.NICHOLS,L.E.BIRD,T.FUJIWARA,H.SUGINOTO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL BINDING OF THE SECOND GENERATTION NON-NUCLEOSIDE INHIBITOR REMARK 1 TITL 2 S-1153 TO HIV-1 REVERSE TRANSCRIPTASE INVOLVES EXTENSIVE REMARK 1 TITL 3 MAIN CHAIN HYDROGEN BONDING REMARK 1 REF J.BIOL.CHEM. V. 275 14316 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 DOI 10.1074/JBC.275.19.14316 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.REN,J.DIPROSE,J.WARREN,R.M.ESNOUF,L.E.BIRD,S.IKEMIZU, REMARK 1 AUTH 2 M.SLATER,J.MILTON,J.BALZARINI,D.I.STUART,D.K.STAMMERS REMARK 1 TITL PHENETHYLTHIAZOLYLTHIOUREA (PETT) NON-NUCLEOSIDE INHIBITORS REMARK 1 TITL 2 OF HIV-1 AND HIV-2 REVERSE TRANSCRIPTASES: STRUCTURAL AND REMARK 1 TITL 3 BIOCHEMICAL ANALYSES REMARK 1 REF J.BIOL.CHEM. V. 275 5633 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 DOI 10.1074/JBC.275.8.5633 REMARK 1 REFERENCE 3 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTALLOGRAPHIC ANALYSIS OF THE BINDING MODES OF REMARK 1 TITL 2 NON-NUCLEOSIDE THIAZOLOISOINDOLINONE INHIBITORS TO HIV-1 REMARK 1 TITL 3 REVERSE TRANSCRIPTASE AND COMPARISON WITH MODELING STUDIES REMARK 1 REF J.MED.CHEM. V. 42 3845 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM990275T REMARK 1 REFERENCE 4 REMARK 1 AUTH A.L.HOPKINS,J.REN,H.TANAKA,M.BABA,M.OKAMATO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL DESIGN OF MKC-442 (EMIVIRINE) ANALOGUES WITH IMPROVED REMARK 1 TITL 2 ACTIVITY AGAINST DRUG-RESISTANT HIV MUTANTS REMARK 1 REF J.MED.CHEM. V. 42 4500 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM990192C REMARK 1 REFERENCE 5 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,J.WARREN,J.BALZARINI, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF REVERSE TRANSCRIPTASE IN COMPLEX WITH REMARK 1 TITL 2 CARBOXANILIDE DERIVATIVES REMARK 1 REF BIOCHEMISTRY V. 37 14394 1998 REMARK 1 REFN ISSN 0006-2960 REMARK 1 DOI 10.1021/BI981309M REMARK 1 REFERENCE 6 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,E.Y.JONES,I.KIRBY,J.KEELING, REMARK 1 AUTH 2 C.K.ROSS,B.A.LARDER,D.I.STUART,D.K.STAMMERS REMARK 1 TITL 3'-AZIDO-3'-DEOXYTHYMIDINE DRUG RESISTANCE MUTATIONS IN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CAN INDUCE LONG RANGE REMARK 1 TITL 3 CONFORMATIONAL CHANGES REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 95 9518 1998 REMARK 1 REFN ISSN 0027-8424 REMARK 1 DOI 10.1073/PNAS.95.16.9518 REMARK 1 REFERENCE 7 REMARK 1 AUTH R.M.ESNOUF,J.REN,E.GARMAN,D.O.SOMERS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K STAMMERS,D.I.STUART REMARK 1 TITL CONTINUOUS AND DISCONTINUOUS CHANGES IN THE UNIT CELL OF REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CRYSTALS ON DEHYDRATION REMARK 1 REF ACTA CRYSTALLOGR.,SECT.D V. 54 938 1998 REMARK 1 REFN ISSN 0907-4449 REMARK 1 DOI 10.1107/S0907444998004284 REMARK 1 REFERENCE 8 REMARK 1 AUTH R.M.ESNOUF,J.REN,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL UNIQUE FEATURES IN THE STRUCTURE OF THE COMPLEX BETWEEN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE AND THE REMARK 1 TITL 3 BIS(HETEROARYL)PIPERAZINE (BHAP) U-90152 EXPLAIN RESISTANCE REMARK 1 TITL 4 MUTATIONS FOR THIS NON-NUCLEOSIDE INHIBITOR REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 94 3984 1997 REMARK 1 REFN ISSN 0027-8424 REMARK 1 DOI 10.1073/PNAS.94.8.3984 REMARK 1 REFERENCE 9 REMARK 1 AUTH A.L HOPKINS,J.REN,R.M.ESNOUF,B.E.WILLCOX,E.Y.JONES,C.K.ROSS, REMARK 1 AUTH 2 T.MIYASAKA,R.T.WALKER,H.TANAKA,D.K.STAMMERS,D.I.STUART REMARK 1 TITL COMPLEXES OF HIV-1 REVERSE TRANSCRIPTASE WITH INHIBITORS OF REMARK 1 TITL 2 THE HEPT SERIES REVEAL CONFORMATIONAL CHANGES RELEVANT TO REMARK 1 TITL 3 THE DESIGN OF POTENT NON-NUCLEOSIDE INHIBITORS REMARK 1 REF J.MED.CHEM. V. 39 1589 1996 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM960056X REMARK 1 REFERENCE 10 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K STAMMERS,D.I.STUART REMARK 1 TITL THE STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH REMARK 1 TITL 2 9-CHLORO-TIBO: LESSONS FOR INHIBITOR DESIGN REMARK 1 REF STRUCTURE V. 3 915 1995 REMARK 1 REFN ISSN 0969-2126 REMARK 1 REFERENCE 11 REMARK 1 AUTH J.REN,R.M.ESNOUF,E.GARMAN,D.O.SOMERS,C.K.ROSS,I.KIRBY, REMARK 1 AUTH 2 J.KEELING,G.DARBY,E.Y.JONES,D.I.STUART,D.K.STAMMERS REMARK 1 TITL HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR REMARK 1 TITL 2 RT-INHIBITOR COMPLEXES REMARK 1 REF NAT.STRUCT.BIOL. V. 2 293 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 12 REMARK 1 AUTH R.M.ESNOUF,J.REN,C.K.ROSS,E.Y.JONES,D.K.STAMMERS,D.I.STUART REMARK 1 TITL MECHANISM OF INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE BY REMARK 1 TITL 2 NON-NUCLEOSIDE INHIBITORS REMARK 1 REF NAT.STRUCT.BIOL. V. 2 303 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 13 REMARK 1 AUTH D.K.STAMMERS,D.O.SOMERS,C.K.ROSS,I.KIRBY,P.H.RAY,J.E.WILSON, REMARK 1 AUTH 2 M.NORMAN,J.REN,R.M.ESNOUF,E.GARMAN,E.Y.JONES,D.I.STUART REMARK 1 TITL CRYSTALS OF HIV-1 REVERSE TRANSCRIPTASE DIFFRACTING TO 2.2 REMARK 1 TITL 2 ANGSTROM RESOLUTION REMARK 1 REF J.MOL.BIOL. V. 242 586 1994 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.1994.1604 REMARK 2 REMARK 2 RESOLUTION. 2.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 89.2 REMARK 3 NUMBER OF REFLECTIONS : 23338 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.205 REMARK 3 FREE R VALUE : 0.287 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1541 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 7756 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 21 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 55.60 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: POSITIONAL RESTRAINTS WERE APPLIED TO REMARK 3 ALL ATOMS DISTANT FROM THE NNRTI-BINDING SITE (DEFINED AS REMARK 3 GREATER THAN 25 ANSTROM FROM THE CA ATOM OF RESIDUE 188) REMARK 3 THROUGHOUT THE REFINEMENT. REMARK 4 REMARK 4 1FKO COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 21-AUG-00. REMARK 100 THE DEPOSITION ID IS D_1000011671. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 30-NOV-97 REMARK 200 TEMPERATURE (KELVIN) : 289 REMARK 200 PH : 5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : PHOTON FACTORY REMARK 200 BEAMLINE : BL-6A REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : FUJI REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23338 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.900 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -1.500 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 89.2 REMARK 200 DATA REDUNDANCY : 3.400 REMARK 200 R MERGE (I) : 0.11800 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 6.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.00 REMARK 200 COMPLETENESS FOR SHELL (%) : 75.3 REMARK 200 DATA REDUNDANCY IN SHELL : 2.70 REMARK 200 R MERGE FOR SHELL (I) : 0.64100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 50.95 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.51 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SEE REFERENCE 13, PH 5, VAPOR REMARK 280 DIFFUSION, SITTING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 70.15000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 37.20000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 54.85000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 37.20000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 70.15000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 54.85000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: HIV-1 RT IS A HETERODIMER CONSISTING OF A P66 AND A P51 REMARK 300 SUBUNITS, THE P51 CONTAINS THE FIRST 440 RESIDUES OF THE P66. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5920 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 46060 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -34.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 PRO B 1 REMARK 465 ILE B 2 REMARK 465 TRP B 88 REMARK 465 GLU B 89 REMARK 465 VAL B 90 REMARK 465 GLN B 91 REMARK 465 LEU B 214 REMARK 465 THR B 215 REMARK 465 THR B 216 REMARK 465 PRO B 217 REMARK 465 ASP B 218 REMARK 465 LYS B 219 REMARK 465 LYS B 220 REMARK 465 HIS B 221 REMARK 465 GLN B 222 REMARK 465 LYS B 223 REMARK 465 GLU B 224 REMARK 465 PRO B 225 REMARK 465 PRO B 226 REMARK 465 PHE B 227 REMARK 465 LEU B 228 REMARK 465 TRP B 229 REMARK 465 MET B 230 REMARK 465 GLY B 231 REMARK 465 TYR B 232 REMARK 465 LEU B 429 REMARK 465 GLU B 430 REMARK 465 LYS B 431 REMARK 465 GLU B 432 REMARK 465 PRO B 433 REMARK 465 ILE B 434 REMARK 465 VAL B 435 REMARK 465 GLY B 436 REMARK 465 ALA B 437 REMARK 465 GLU B 438 REMARK 465 THR B 439 REMARK 465 PHE B 440 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO B 133 C - N - CA ANGL. DEV. = 10.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 14 107.27 -41.72 REMARK 500 TRP A 24 140.71 -34.73 REMARK 500 GLU A 53 7.20 -69.43 REMARK 500 ASN A 57 147.81 -174.20 REMARK 500 ASP A 67 -22.48 91.56 REMARK 500 LEU A 74 134.23 -175.01 REMARK 500 PHE A 116 -3.58 -58.92 REMARK 500 THR A 128 31.35 -95.52 REMARK 500 GLU A 138 -78.00 -60.58 REMARK 500 THR A 139 -68.66 -145.60 REMARK 500 SER A 156 -63.16 -29.86 REMARK 500 ILE A 167 -14.85 -49.03 REMARK 500 ASN A 175 66.86 -112.49 REMARK 500 ASP A 177 -9.76 -59.55 REMARK 500 TYR A 183 113.76 -165.86 REMARK 500 MET A 184 -136.99 43.65 REMARK 500 MET A 230 87.00 8.15 REMARK 500 GLN A 242 94.51 -59.74 REMARK 500 PRO A 243 136.07 -32.71 REMARK 500 ASP A 250 -82.30 -64.66 REMARK 500 ARG A 284 115.76 -27.94 REMARK 500 THR A 286 122.71 -39.99 REMARK 500 LYS A 311 -75.12 -84.40 REMARK 500 GLU A 312 89.48 -57.02 REMARK 500 PRO A 321 -33.48 -36.67 REMARK 500 GLN A 332 -64.01 -91.53 REMARK 500 PRO A 345 134.90 -32.34 REMARK 500 PHE A 346 -15.03 69.45 REMARK 500 MET A 357 158.99 -44.12 REMARK 500 ARG A 358 -29.48 -36.92 REMARK 500 ALA A 360 -91.18 -125.19 REMARK 500 TRP A 410 147.29 -170.68 REMARK 500 ASN A 418 60.14 -66.54 REMARK 500 TYR A 427 161.32 165.55 REMARK 500 TYR A 441 78.25 -103.48 REMARK 500 ALA A 445 149.50 -172.99 REMARK 500 ASP A 488 14.57 -67.98 REMARK 500 SER A 489 -64.45 -93.19 REMARK 500 LEU A 491 -42.17 -26.02 REMARK 500 ALA A 508 36.55 -89.37 REMARK 500 GLN A 509 52.79 15.61 REMARK 500 GLN A 512 143.37 -173.37 REMARK 500 ILE A 542 -77.74 -95.53 REMARK 500 GLU B 44 0.13 -50.00 REMARK 500 GLU B 53 -9.55 -56.53 REMARK 500 PHE B 61 -169.36 -163.66 REMARK 500 SER B 68 121.33 151.19 REMARK 500 ASN B 103 156.65 -38.07 REMARK 500 PHE B 116 -6.49 -53.62 REMARK 500 GLU B 122 -75.19 -29.81 REMARK 500 REMARK 500 THIS ENTRY HAS 73 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EFZ A 999 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1RTV RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1RTH RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 1051U91 REMARK 900 RELATED ID: 1VRU RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH ALPHA-APA REMARK 900 RELATED ID: 1RTI RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH HEPT REMARK 900 RELATED ID: 1RTJ RELATED DB: PDB REMARK 900 HIV-1 RT REMARK 900 RELATED ID: 1REV RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH 9-CL-TIBO REMARK 900 RELATED ID: 1RT1 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH MKC-442 REMARK 900 RELATED ID: 1RT2 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH TNK-651 REMARK 900 RELATED ID: 1KLM RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BHAP (U-90152) REMARK 900 RELATED ID: 1RT3 RELATED DB: PDB REMARK 900 AZT DRUG RESISTANT HIV-1 RT MUTANT (RTMC) COMPLEXED WITH 1051U91 REMARK 900 RELATED ID: 1RT4 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-781 REMARK 900 RELATED ID: 1RT5 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-10 REMARK 900 RELATED ID: 1RT6 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-38 REMARK 900 RELATED ID: 1RT7 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH UC-84 REMARK 900 RELATED ID: 1C0T RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BM+21.1326 REMARK 900 RELATED ID: 1C0U RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH BM+50.0934 REMARK 900 RELATED ID: 1C1B RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH GCA-186 REMARK 900 RELATED ID: 1C1C RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH TNK-6123 REMARK 900 RELATED ID: 1DTQ RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH PETT-1 REMARK 900 RELATED ID: 1DTT RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH PETT-2 REMARK 900 RELATED ID: 1EP4 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH S-1153 REMARK 900 RELATED ID: 1FK9 RELATED DB: PDB REMARK 900 HIV-1 RT COMPLEXED WITH DMP-266 (EFAVIRENZ) REMARK 900 RELATED ID: 1FKP RELATED DB: PDB REMARK 900 NNRTI RESISTANT K103N MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE DBREF 1FKO A 1 543 UNP P04585 POL_HV1H2 587 1129 DBREF 1FKO B 1 440 UNP P04585 POL_HV1H2 587 1026 SEQADV 1FKO ASN A 103 UNP P04585 LEU 258 ENGINEERED MUTATION SEQADV 1FKO ASN B 103 UNP P04585 LEU 258 ENGINEERED MUTATION SEQRES 1 A 543 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 A 543 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 A 543 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 A 543 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 A 543 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 A 543 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 A 543 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 A 543 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS ASN LYS SEQRES 9 A 543 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 A 543 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 A 543 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 A 543 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 A 543 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 A 543 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 A 543 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 A 543 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 A 543 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 A 543 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 A 543 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 A 543 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 A 543 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 A 543 ILE LYS VAL ARG GLN LEU CSD LYS LEU LEU ARG GLY THR SEQRES 23 A 543 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 A 543 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 A 543 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 A 543 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 A 543 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 A 543 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 A 543 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 A 543 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 A 543 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 A 543 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 A 543 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 A 543 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE TYR VAL SEQRES 35 A 543 ASP GLY ALA ALA ASN ARG GLU THR LYS LEU GLY LYS ALA SEQRES 36 A 543 GLY TYR VAL THR ASN ARG GLY ARG GLN LYS VAL VAL THR SEQRES 37 A 543 LEU THR ASP THR THR ASN GLN LYS THR GLU LEU GLN ALA SEQRES 38 A 543 ILE TYR LEU ALA LEU GLN ASP SER GLY LEU GLU VAL ASN SEQRES 39 A 543 ILE VAL THR ASP SER GLN TYR ALA LEU GLY ILE ILE GLN SEQRES 40 A 543 ALA GLN PRO ASP GLN SER GLU SER GLU LEU VAL ASN GLN SEQRES 41 A 543 ILE ILE GLU GLN LEU ILE LYS LYS GLU LYS VAL TYR LEU SEQRES 42 A 543 ALA TRP VAL PRO ALA HIS LYS GLY ILE GLY SEQRES 1 B 440 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 B 440 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 B 440 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 B 440 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 B 440 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 B 440 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 B 440 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 B 440 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS ASN LYS SEQRES 9 B 440 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 B 440 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 B 440 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 B 440 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 B 440 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 B 440 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 B 440 TYR MET ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 B 440 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 B 440 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 B 440 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 B 440 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 B 440 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 B 440 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 B 440 ILE LYS VAL ARG GLN LEU CYS LYS LEU LEU ARG GLY THR SEQRES 23 B 440 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 B 440 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 B 440 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 B 440 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 B 440 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 B 440 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 B 440 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 B 440 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 B 440 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 B 440 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 B 440 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 B 440 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE MODRES 1FKO CSD A 280 CYS 3-SULFINOALANINE HET CSD A 280 8 HET EFZ A 999 21 HETNAM CSD 3-SULFINOALANINE HETNAM EFZ (-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1, HETNAM 2 EFZ 4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE HETSYN CSD S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE HETSYN EFZ DMP-266; EFAVIRENZ FORMUL 1 CSD C3 H7 N O4 S FORMUL 3 EFZ C14 H9 CL F3 N O2 HELIX 1 1 THR A 27 GLY A 45 1 19 HELIX 2 2 PHE A 77 THR A 84 1 8 HELIX 3 3 HIS A 96 LEU A 100 5 5 HELIX 4 4 GLY A 112 VAL A 118 5 7 HELIX 5 5 PHE A 124 TYR A 127 5 4 HELIX 6 6 LYS A 154 ASN A 175 1 22 HELIX 7 7 GLU A 194 ARG A 211 1 18 HELIX 8 8 VAL A 254 GLN A 269 1 16 HELIX 9 9 THR A 296 LEU A 310 1 15 HELIX 10 10 ASN A 363 TRP A 383 1 21 HELIX 11 11 GLN A 394 THR A 403 1 10 HELIX 12 12 THR A 473 ASP A 488 1 16 HELIX 13 13 SER A 499 ALA A 508 1 10 HELIX 14 14 SER A 515 LYS A 528 1 14 HELIX 15 15 THR B 27 GLU B 44 1 18 HELIX 16 16 PHE B 77 ARG B 83 1 7 HELIX 17 17 GLY B 112 VAL B 118 5 7 HELIX 18 18 ASP B 121 LYS B 126 1 6 HELIX 19 19 TYR B 127 ALA B 129 5 3 HELIX 20 20 SER B 134 GLU B 138 5 5 HELIX 21 21 LYS B 154 PHE B 160 1 7 HELIX 22 22 PHE B 160 LYS B 173 1 14 HELIX 23 23 GLU B 194 GLY B 213 1 20 HELIX 24 24 VAL B 254 SER B 268 1 15 HELIX 25 25 VAL B 276 LEU B 283 1 8 HELIX 26 26 THR B 296 LEU B 310 1 15 HELIX 27 27 ASN B 363 GLY B 384 1 22 HELIX 28 28 GLN B 394 TRP B 406 1 13 HELIX 29 29 PRO B 420 GLN B 428 1 9 SHEET 1 A 3 ILE A 47 LYS A 49 0 SHEET 2 A 3 ILE A 142 TYR A 146 -1 O GLN A 145 N SER A 48 SHEET 3 A 3 ALA A 129 ILE A 132 -1 N PHE A 130 O TYR A 144 SHEET 1 B 2 VAL A 60 ILE A 63 0 SHEET 2 B 2 ARG A 72 VAL A 75 -1 O ARG A 72 N ILE A 63 SHEET 1 C 3 SER A 105 ASP A 110 0 SHEET 2 C 3 ASP A 186 SER A 191 -1 O LEU A 187 N LEU A 109 SHEET 3 C 3 VAL A 179 TYR A 183 -1 N VAL A 179 O GLY A 190 SHEET 1 D 4 PHE A 227 TRP A 229 0 SHEET 2 D 4 TYR A 232 LEU A 234 -1 N TYR A 232 O TRP A 229 SHEET 3 D 4 TRP A 239 VAL A 241 -1 N THR A 240 O GLU A 233 SHEET 4 D 4 HIS A 315 GLY A 316 -1 N GLY A 316 O TRP A 239 SHEET 1 E 2 TRP A 252 THR A 253 0 SHEET 2 E 2 VAL A 292 ILE A 293 -1 N ILE A 293 O TRP A 252 SHEET 1 F 5 LYS A 347 ALA A 355 0 SHEET 2 F 5 GLN A 336 GLU A 344 -1 N TRP A 337 O TYR A 354 SHEET 3 F 5 ILE A 326 GLY A 333 -1 O ILE A 326 N TYR A 342 SHEET 4 F 5 LYS A 388 LEU A 391 1 O LYS A 388 N ALA A 327 SHEET 5 F 5 TRP A 414 PHE A 416 1 N GLU A 415 O PHE A 389 SHEET 1 G 2 HIS A 361 THR A 362 0 SHEET 2 G 2 GLN A 512 SER A 513 -1 O GLN A 512 N THR A 362 SHEET 1 H 3 GLU A 438 TYR A 441 0 SHEET 2 H 3 GLU A 492 THR A 497 1 O GLU A 492 N GLU A 438 SHEET 3 H 3 LYS A 530 TRP A 535 1 O LYS A 530 N VAL A 493 SHEET 1 I 3 ASP A 443 ALA A 446 0 SHEET 2 I 3 GLY A 453 VAL A 458 -1 N LYS A 454 O ALA A 445 SHEET 3 I 3 GLN A 464 LEU A 469 -1 O LYS A 465 N TYR A 457 SHEET 1 J 3 ILE B 47 LYS B 49 0 SHEET 2 J 3 ILE B 142 TYR B 146 -1 O GLN B 145 N SER B 48 SHEET 3 J 3 PHE B 130 ILE B 132 -1 O PHE B 130 N TYR B 144 SHEET 1 K 2 VAL B 60 ILE B 63 0 SHEET 2 K 2 ARG B 72 VAL B 75 -1 N ARG B 72 O ILE B 63 SHEET 1 L 3 SER B 105 ASP B 110 0 SHEET 2 L 3 ASP B 186 SER B 191 -1 O LEU B 187 N LEU B 109 SHEET 3 L 3 ILE B 178 TYR B 183 -1 O VAL B 179 N GLY B 190 SHEET 1 M 2 TRP B 252 THR B 253 0 SHEET 2 M 2 VAL B 292 ILE B 293 -1 N ILE B 293 O TRP B 252 SHEET 1 N 5 LYS B 347 ALA B 355 0 SHEET 2 N 5 GLN B 336 GLU B 344 -1 N TRP B 337 O TYR B 354 SHEET 3 N 5 ILE B 326 GLY B 333 -1 N ILE B 326 O TYR B 342 SHEET 4 N 5 LYS B 388 LEU B 391 1 O LYS B 388 N ALA B 327 SHEET 5 N 5 GLU B 413 PHE B 416 1 O GLU B 413 N PHE B 389 LINK C LEU A 279 N CSD A 280 1555 1555 1.33 LINK C CSD A 280 N LYS A 281 1555 1555 1.38 CISPEP 1 PRO A 225 PRO A 226 0 -0.62 CISPEP 2 PRO A 420 PRO A 421 0 0.13 SITE 1 AC1 11 LEU A 100 LYS A 101 ASN A 103 VAL A 179 SITE 2 AC1 11 TYR A 181 TYR A 188 VAL A 189 GLY A 190 SITE 3 AC1 11 PHE A 227 LEU A 234 TYR A 318 CRYST1 140.300 109.700 74.400 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007128 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009116 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013441 0.00000